# Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

> **NCT00297076** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 406 (—)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** GW873140

## Key facts

- **NCT ID:** NCT00297076
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 406 (—)
- **Last updated:** 2009-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297076, "Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00297076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*